Biosciences

Basel, Switzerland

Biosciences

Basel, Switzerland

Time filter

Source Type

The paper, SPX-101 Is A Novel ENaC-Targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport 1, investigates the in vitro and in vivo efficacy of SPX-101, a peptide mimetic of SPLUNC1's natural regulation of ENaC activity. SPX-101 is an inhaled peptide with a novel, biological mechanism that regulates epithelial sodium channel (ENaC) density in the airway.  The drug is designed to restore a cellular pathway in the lung that promotes airway hydration and mucociliary clearance, which are dysfunctional in CF. The mechanism of action of SPX-101 is independent of the genetic mutations that cause CF, which makes it a potential therapy for all CF patients. The authors used biochemical approaches to demonstrate that SPX-101 binds specifically to ENaC, but not structurally similar proteins, inducing ENaC internalization in human bronchial epithelial cells from healthy and CF donors. Removal of ENaC from the plasma membrane caused a significant reduction in amiloride sensitive current and increased hydration of the airway epithelial cell cultures.  When tested in vivo, they demonstrated that SPX-101 significantly increased survival of βENaC transgenic mice and increased mucus transport in mouse and sheep models of CF lung disease.  The authors concluded that via this unique biological mechanism of action in removing ENaC from the cell surface, SPX-101 promotes a durable inhibition of sodium absorption resulting in increased mucus transport. "We are honored to have the opportunity to share our work on SPX-101 with the research and clinical community through this publication in The Blue Journal," said Timm Crowder, PhD, Senior Vice President, Technical Operations for Spyryx and one of the authors of the paper. "It highlights the opportunity for a treatment approach that extends beyond mutation specific therapies, targeting treatment for all CF patients. The strong preclinical data supporting SPX-101's ability to promote airway hydration and mucociliary clearance suggest high potential for our product to deliver clinically meaningful benefit, which we will thoroughly investigate in our Phase 2 study beginning mid-2017." About Cystic Fibrosis CF is an autosomal recessive genetic disorder affecting approximately 75,000 individuals worldwide.  The disease is caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CF profoundly affects the lungs and respiratory tract and is characterized by dehydration of the airway surface, resulting in reduced mucus clearance, the lung's principle mechanism for maintaining a clean environment. The mucus becomes thick and sticky, progressively accumulating into obstructions that block airflow and result in recurrent colonization of the airways by viruses and bacteria.  These pathogens lead to frequent, acute lung infections, chronic inflammation, exacerbations, and impaired lung function. The long-term result of the disease, is progressive, permanent tissue damage and scarring (fibrosis) in the lung.  No cure for cystic fibrosis is known, although several treatments have been approved to address the underlying cause of the disease in some patients. Despite currently available treatment, the median age of survival for CF patients is approximately 40 years of age. About Spyryx Biosciences Spyryx Biosciences is a privately held, clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases. Spyryx's lead clinical candidate, SPX-101, is a novel treatment for cystic fibrosis that has successfully completed a Phase 1 study in healthy volunteers and is advancing into Phase 2 in CF patients. The product has demonstrated a robust ability to restore mucociliary clearance in animal models of the disease and has the potential to improve lung function in all cystic fibrosis patients independent of their CFTR mutation. The Spyryx leadership team and scientific staff have extensive experience in the development of respiratory medicines and work closely with a broad group of clinical and scientific experts in the pulmonary field. Spyryx is funded by a first tier syndicate of life science investors, including Canaan Partners, 5AM Ventures and Hatteras Venture Partners. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com. 1SPX-101 is a novel ENaC-targeted therapeutic for cystic fibrosis that restores mucus transport 1Spyryx Biosciences, 801-10 Capitola Dr, Durham, NC, 27713. 2Department of Research Mount Sinai Medical Center, Miami Beach, FL, 33140. 3Marsico Lung institute and Department of Cell Biology and Physiology, 111 Mason Farm Rd, The University of North Carolina, Chapel Hill, NC, 27599-7248. #Current Address: Duke University Medical Center, Department of Medicine, Durham, NC 27710 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-american-journal-of-respiratory-and-critical-care-medicine-publishes-study-of-spyryx-biosciences-spx-101-a-novel-enac-targeted-therapeutic-for-cystic-fibrosis-that-restores-mucus-transport-300454404.html


DAVIS, Calif.--(BUSINESS WIRE)--Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology company that creates value for farmers while benefitting the environment and enhancing human health, today released its financial and business results for the first quarter ended March 31, 2017. Revenues for the quarter were up 19 percent to $1.0 million, compared to $852,000 for the first quarter of 2016. The increase reflects higher contract and grant revenue, primarily the result of a new agreement. Operating expenses for the first quarter were $5.0 million compared to $5.8 million for the same period in the prior year. The company’s loss from operations was $4.0 million in the first quarter of 2017 compared to $4.9 million in the first quarter of 2016. Net loss and net loss attributable to common stockholders in the first quarter of 2017 was $4.2 million, compared to $5.2 million in the comparable period in 2016. Cash on hand and liquid investments at the end of the first quarter totaled $48.5 million. “We are pleased with our progress in Q1 of this year, having increased revenue and lowered our operating expenses, reducing our loss by 20 percent compared to the same period last year,” said Raj Ketkar, president and CEO of Arcadia. “We also met with several of our key business partners, who continue to be committed to the commercialization of our rich pipeline in our yield trait and food ingredient platforms.” Arcadia made the following business and technical achievements in the first quarter of 2017: Since the close of the first quarter, Arcadia has announced the following: In the first quarter of 2017, revenues were $1.0 million compared to revenues of $852,000 in the first quarter of 2016, a 19 percent improvement. The quarter-over-quarter increase was driven by additional revenue from a new contract research agreement in 2017. In the first quarter of 2017, operating expenses totaled $5.0 million, down from $5.8 million in the first quarter of 2016, a decrease of $804,000 or 14 percent. Cost of product revenues decreased by $41,000 as a result of slightly lower sales when comparing the respective periods. Research and development (R&D) spending decreased by $379,000 and general and administrative (SG&A) expenses decreased by $384,000. Both decreases were driven primarily by lower salaries and benefits, mainly the result of workforce reductions made during 2016. Net loss attributable to common stockholders for the first quarter of 2017 was $4.2 million, or a loss of $0.10 per share, a 19 percent improvement from the $5.2 million loss in the first quarter of 2016. The company has scheduled a conference call for 4:30 p.m. Eastern (1:30 p.m. Pacific) today, May 10, to discuss first-quarter financial results and key strategic achievements. Interested participants can join the conference call using the following numbers: A live webcast of the conference call will be available on the “Investors” section of the Arcadia’s website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company’s investor website. “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success; the company’s traits, commercial products, and collaborations; and the company’s ability to manage the regulatory processes for its traits and commercial products. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s and its partners’ ability to develop commercial products incorporating its traits and to complete the regulatory review process for such products; the company’s compliance with laws and regulations that impact the company’s business, and changes to such laws and regulations; and the company’s future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company’s financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled “Risk Factors” in the company's Annual Report on Form 10-K for the year ended December 31, 2016. These documents are on the SEC Filings section of the “Investors” section of the company’s website at www.arcadiabio.com. All information provided in this release and in the attachments is as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update this information. Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. For more information, visit www.arcadiabio.com.


MADISON, Wis., May 11, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces financial results for first quarter of 2017.  Management will host a teleconference and live webcast to review these results, including a review of corporate performance, at 4:30 PM ET today. Summary of Q1 and Q2 2017 Accomplishments to Date: “We continue to advance the clinical development of our lead product candidate, CLR 131, now in a fourth cohort of a Phase 1 trial for multiple myeloma, and an NCI-supported Phase 2 study in hematological malignancies. We have also successfully worked to enhance our intellectual property portfolio to protect the value in our pipeline,” said Jim Caruso, president and CEO of Cellectar Biosciences.  “The additions to our management team and board underscore our commitment to progressing Cellectar strategically as we continue our clinical and preclinical development programs.” Research and development expenses were $1.9 million, an increase of $0.8 million from the same period the prior year, largely a result of the increase in activities surrounding the initiation of the company’s Phase 2 clinical trial of CLR 131 in hematologic malignancies in addition to the ongoing Phase 1 trial in relapse/refractory multiple myeloma.  General and administrative expenses totaled $1.0 million, consistent with Q1 2016. The operating loss was $2.8 million, compared to $2.0 million in 2016.  Net loss for the first quarter of 2017 was $2.9 million, or $0.24 per share, compared to net income of $0.8 million, or $0.96 per share, for the first quarter of 2016. As of March 31, 2017, Cellectar reported $11.2 million in cash and cash equivalents on hand, compared to $11.4 million in cash and cash equivalents as of December 31, 2016. Finally, the company received approximately $3 million from warrants exercised during the quarter, which extends Cellectar’s available cash and cash equivalents to fund planned operations into the second quarter of 2018.  This is an improvement from the previous guidance of funding into the first quarter 2018.  Additional capital will be required for operations beyond the second quarter of 2018. Conference Call Details Cellectar will be holding a conference call at 4:30 PM ET today to review Q1 2017 financial results, and corporate performance. The call may be accessed by dialing (888) 646-8293 (US domestic) or (973) 453-3065 (international), or participate via webcast at http://edge.media-server.com/m/p/2qdweuf4. The live and archived webcast can also be accessed via the company’s website at http://investor.cellectar.com/events.cfm. About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells.  Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs.  These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers.  Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging.  The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload.  CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma.  In addition, the company has initiated a Phase II clinical study to assess efficacy in a range of B-cell malignancies.   The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.  For more information please visit www.cellectar.com. This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.  A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016.  These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.


News Article | May 11, 2017
Site: phys.org

Their research - 'Root hydrotropism is controlled via a cortex-specific growth mechanism' - sheds new light on which part of the root perceives a water signal, and which tissues then change their growth to make the root change direction. Their findings have been published in Nature Plants. Lead researcher, Dr Daniela Dietrich from the School of Biosciences at Nottingham, said: "Even when most of the root tip was removed by laser or scalpel, roots of the model plant Arabidopsis thaliana still responded to a water gradient in the medium they were growing on. This showed that hydrotropism - the way in which plant roots respond to moisture content of soil - depends on perception and response in the elongation zone, a rapidly growing area of the root just behind the tip." So, how do plants search for water? Hydrotropism is less well understood than responses to other environmental cues such as gravity, light or touch. A group of cells at the tip of the root, known as the columella, are used to sense gravity, and the researchers wanted to know whether the same cells were involved in sensing water. Using laser ablation, which can destroy cells with pinpoint accuracy, they showed that columella cells are not necessary for hydrotropism. They also wanted to understand if hydrotropism requires the response of a specific root tissue. The plant hormone Abscisic Acid (ABA) is key to the molecular signalling pathway for hydrotropism, as is a gene called MIZ1. By taking mutants in which key components of this signalling cascade for hydrotropism were missing, and then inducing the expression of those same key components in specific tissue layers only, the researchers were able to demonstrate that the cortex, the tissue layer directly below the epidermis, is where root growth changes in response to water perception. Dr Daniela Dietrich, the study's lead researcher at the University of Nottingham, said: "We were surprised to see that in both cases, expression in the cortex was able to rescue the hydrotropism response. For the gravitropic response, which involves auxin, the epidermis is important, so it is quite interesting to see that these two environmental responses are controlled by different plant hormones, acting on different root tissues." The researchers also used mathematical modelling to see whether growth changes in the cortex tissue layer alone are enough to change the direction of the root. When an existing model was adapted so that only cortex cells on one side of the root started to elongate earlier, the changes in root tip direction predicted by the model were reflected in the plant experiments. Explore further: Gardening in Space with HydroTropi More information: Daniela Dietrich et al. Root hydrotropism is controlled via a cortex-specific growth mechanism, Nature Plants (2017). DOI: 10.1038/nplants.2017.57


This report studies Oil Seed Crop Protection in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Adama Agricultural Solutions American Vanguard Corporation Arysta LifeScience BASF Bayer Bioworks Cheminova Chemtura AgroSolutions Dow DuPont FMC Corporation IsAgro Ishihara Sangyo Kaisha Marrone Bio Innovations Monsanto Natural Industries -Novozymes Nufarm Ltd Syngenta International Valent Biosciences Corp By types, the market can be split into Synthetic Pesticides Biopesticides By Application, the market can be split into Sunflower Rape Sesame Groundnut Linseed Safflower Others By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India Global Oil Seed Crop Protection Market Professional Survey Report 2017 1 Industry Overview of Oil Seed Crop Protection 1.1 Definition and Specifications of Oil Seed Crop Protection 1.1.1 Definition of Oil Seed Crop Protection 1.1.2 Specifications of Oil Seed Crop Protection 1.2 Classification of Oil Seed Crop Protection 1.2.1 Synthetic Pesticides 1.2.2 Biopesticides 1.3 Applications of Oil Seed Crop Protection 1.3.1 Sunflower 1.3.2 Rape 1.3.3 Sesame 1.3.4 Groundnut 1.3.5 Linseed 1.3.6 Safflower 1.3.7 Others 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India 2 Manufacturing Cost Structure Analysis of Oil Seed Crop Protection 2.1 Raw Material and Suppliers 2.2 Manufacturing Cost Structure Analysis of Oil Seed Crop Protection 2.3 Manufacturing Process Analysis of Oil Seed Crop Protection 2.4 Industry Chain Structure of Oil Seed Crop Protection 8 Major Manufacturers Analysis of Oil Seed Crop Protection 8.1 Adama Agricultural Solutions 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.2.1 Product A 8.1.2.2 Product B 8.1.3 Adama Agricultural Solutions 2016 Oil Seed Crop Protection Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 Adama Agricultural Solutions 2016 Oil Seed Crop Protection Business Region Distribution Analysis 8.2 American Vanguard Corporation 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.2.1 Product A 8.2.2.2 Product B 8.2.3 American Vanguard Corporation 2016 Oil Seed Crop Protection Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 American Vanguard Corporation 2016 Oil Seed Crop Protection Business Region Distribution Analysis 8.3 Arysta LifeScience 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Product A 8.3.2.2 Product B 8.3.3 Arysta LifeScience 2016 Oil Seed Crop Protection Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 Arysta LifeScience 2016 Oil Seed Crop Protection Business Region Distribution Analysis 8.4 BASF 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.2.1 Product A 8.4.2.2 Product B 8.4.3 BASF 2016 Oil Seed Crop Protection Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 BASF 2016 Oil Seed Crop Protection Business Region Distribution Analysis 8.5 Bayer 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.2.1 Product A 8.5.2.2 Product B 8.5.3 Bayer 2016 Oil Seed Crop Protection Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 Bayer 2016 Oil Seed Crop Protection Business Region Distribution Analysis 8.6 Bioworks 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.2.1 Product A 8.6.2.2 Product B 8.6.3 Bioworks 2016 Oil Seed Crop Protection Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 Bioworks 2016 Oil Seed Crop Protection Business Region Distribution Analysis 8.7 Cheminova 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.2.1 Product A 8.7.2.2 Product B 8.7.3 Cheminova 2016 Oil Seed Crop Protection Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 Cheminova 2016 Oil Seed Crop Protection Business Region Distribution Analysis 8.8 Chemtura AgroSolutions 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.2.1 Product A 8.8.2.2 Product B 8.8.3 Chemtura AgroSolutions 2016 Oil Seed Crop Protection Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Chemtura AgroSolutions 2016 Oil Seed Crop Protection Business Region Distribution Analysis 8.9 Dow 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.2.1 Product A 8.9.2.2 Product B 8.9.3 Dow 2016 Oil Seed Crop Protection Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 Dow 2016 Oil Seed Crop Protection Business Region Distribution Analysis 8.10 DuPont 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.2.1 Product A 8.10.2.2 Product B 8.10.3 DuPont 2016 Oil Seed Crop Protection Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 DuPont 2016 Oil Seed Crop Protection Business Region Distribution Analysis 8.11 FMC Corporation 8.12 IsAgro 8.13 Ishihara Sangyo Kaisha 8.14 Marrone Bio Innovations 8.15 Monsanto 8.16 Natural Industries -Novozymes 8.17 Nufarm Ltd 8.18 Syngenta International 8.19 Valent Biosciences Corp For more information, please visit https://www.wiseguyreports.com/sample-request/1270936-global-oil-seed-crop-protection-market-professional-survey-report-2017


BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading genome engineering company, announced today that the European Patent Office (EPO) has granted a broad CRISPR-Cas9 genome editing patent to The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier. Caribou holds the exclusive license to the foundational CRISPR-Cas9 patent estate from the University of California and the University of Vienna. The European patent, EP 2 800 811, includes claims covering the widely adopted CRISPR-Cas9 single-guide RNA compositions for use in any non-cellular and cellular setting, including eukaryotic cells, such as mammalian, human and plant cells. The patent also covers methods of using the technology in in vitro and ex vivo settings using the single-guide RNA format. " We are delighted by the EPO’s decision to recognize the foundational CRISPR-Cas9 discoveries of Jennifer Doudna, Emmanuelle Charpentier, and their colleagues through this important and far-reaching patent," remarked Dr. Rachel Haurwitz, President and CEO of Caribou. " This patent represents a significant addition to the extensive and leading IP portfolio Caribou is building." The European patent is validated in approximately forty European countries, including Germany, Italy, France, Spain, and Switzerland. The EPO grant follows grants by the United Kingdom's Intellectual Property Office (UKIPO) of patents from this family. The UK patents relate to the CRISPR-Cas9 gene editing systems involving single-guide RNA in both non-cellular and cellular settings (UK Patent No. 2518764) and chimeric CRISPR-Cas9 systems in which the Cas9 protein is modified to provide alternative DNA-modulating activities (UK Patent No. 2537000). About Caribou Biosciences Caribou is a leading company in CRISPR genome engineering founded by pioneers of CRISPR-Cas9 biology based on research carried out in the Doudna Laboratory at the University of California, Berkeley. Caribou’s tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. Licenses are available from Caribou in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology. Interested companies can contact Caribou at licensing@cariboubio.com. For more information about Caribou, visit www.cariboubio.com and follow the Company @CaribouBio. “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.


News Article | May 10, 2017
Site: www.eurekalert.org

Big data is a buzzword that is often used in customer behavior analyses or social network modeling. However, big data is also being created in biology, where modern high-throughput DNA sequencing can easily produce loads of data. Exponential decrease in the cost of sequencing during this decade has made it possible to analyze whole populations of organisms instead of a small set or only one selected individual. Population-level data opens up completely new ways of studying the organisms. For example, history of the species can be inferred from patterns imprinted in the genomes by long-term evolution and more recent natural selection. These types of analyses have earlier been carried out for humans where there already exists plenty of data, but the low cost of DNA sequencing makes it now possible to look at altogether different species, such as ones of importance to forestry and Finnish culture. Here, researchers collected birch samples from twelve sites spanning a range from Ireland to the heart of Siberia and from Loppi, southern Finland, up to Kittilä, northern Finland. "The project produced altogether over 700 Gigabases of genome sequence, resulting in over 20 Terabytes of data from various analyses," reports Research Director Petri Auvinen from DNA sequencing and genomics lab. Computational analyses showed population bottlenecks, periods of extremely low number of individuals, at times with known climatic upheaval. The first bottleneck occurred around 66 million years ago (Mya), at the time when dinosaurs became extinct, followed by bottlenecks 34 Mya, 14.5 Mya, and 1 million years ago. "This may be connected with speciation events in birches, since fossil evidence shows that the alders and birches split already around 60 Mya, and the white-barked birches had appeared around 10 million years ago," says Professor Victor Albert. After the last bottleneck the birch population has been steadily increasing. The last ice age split the birches into two populations, a European and a Siberian one, which have been mixing in Finland since the melting of the continental ice sheet. In addition to silver birch, the genomes of six other birch species were also sequenced, as well as two closely related alders, grey and black alder. Making a distinction between diploid silver birches and tetraploid downy birches (which have doubled their genomes compared to diploids) proved to be more difficult than expected, since some of the sampled silver birches themselves turned out to have four sets of chromosomes. "This illustrates that there has been and most likely still is some gene flow between the two species," says researcher Jarkko Salojärvi from the Department of Biosciences. In addition to population genomic analyses, the project assembled a reference genome for silver birch and predicted its genes. "This hybrid assembly combined data from four different next generation sequencing platforms," says researcher Olli-Pekka Smolander. Population genomic analyses identified 900 genes under natural selection, which have evolved birch into its current state as a cold-tolerant and fast-growing pioneer species. Genes under selection are in key positions in the development of birch phenotypes, which is why breeding could focus on these key genes when developing new birch lines for biotechnology purposes. "When the candidate genes have been identified, further breeding is rather rapid since birch is the only tree species that in special growth conditions can be made to flower within less than one year. This makes it possible to grow one breeding population in one year," says Professor Jaakko Kangasjärvi. "A unique trait in a single birch line can result from a mutation in a single gene, for example, the weeping birch cultivar known from gardens, Betula pendula "Youngii", had a truncated LAZY gene," says Professor Yrjö Helariutta. A mutation in this gene is known to produce a relaxed phenotype also in maize and thale cress. The research was carried out by D.Sc Jarkko Salojärvi and Professor Jaakko Kangasjärvi (Dept. Biosciences, University of Helsinki, Finland), D.Sc Olli-Pekka Smolander and Petri Auvinen (Institute of Biotechnology, University of Helsinki , Finland), Professor Yrjö Helariutta (Dept. Biosciences and Institute of Biotechnology, University of Helsinki and Sainsbury laboratories, Cambridge, UK), and Professor Victor Albert (University at Buffalo, USA). The gene models were curated by researchers from University of Helsinki, University of Turku, University of Eastern Finland, Estonian University of Life Sciences, Umeå University, and the Natural Resources Institute of Finland.


Browse 35 Tables and 11 Figures, 22 Companies, spread across 112 pages available at http://www.reportsnreports.com/reports/983974-hemophilia-b-pipeline-review-h1-2017.html . Hemophilia B market companies are Alnylam Pharmaceuticals Inc, Amarna Therapeutics BV, Bayer AG, Bioverativ Inc, Catalyst, Biosciences Inc, China Biologic Products Inc, CSL Ltd, Dimension Therapeutics Inc, Genethon SA, Green Cross Corp, MolMed SpA, Novo Nordisk A/S, OPKO Biologics Ltd, Pfizer Inc, Pharming Group NV, Promethera Biosciences SA, RegenxBio Inc, rEVO Biologics Inc, Sangamo Therapeutics Inc, Shire Plc, Spark Therapeutics Inc, UniQure NV. Market Hemophilia B key player's reviews involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 9, 4, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Scope: The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders). The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The Hemophilia B market pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects and latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders). Reasons to buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Explore more reports on Pharmaceuticals at http://www.reportsnreports.com/market-research/pharmaceuticals/ . ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


News Article | May 9, 2017
Site: www.marketwired.com

VANCOUVER, BC--(Marketwired - May 9, 2017) -  Lexington Biosciences, Inc. ( : LNB) ( : LNB) ( : LNB.CN) (the "Company" or "Lexington"), a development-stage medical device company operating within the healthcare industry, is pleased to announce that the Company has commenced trading on the Canadian Securities Exchange (the "Exchange") effective May 9, 2017 under the symbol "LNB." Transaction and Private Placement The Company completed an acquisition on December 21, 2016, whereby the Company acquired 100% of the issued and outstanding common shares of Lexington Biosciences Inc. (now Lexington Biosciences Holdings Corp.), a company incorporated under the laws of British Columbia ("Lexington Holdings") in exchange for 8,000,001 common shares issued to the shareholders of Lexington Holdings. Certain shares issued to the principals of the Company are subject to escrow conditions required by applicable securities laws and Exchange requirements. In connection with the acquisition, the Company closed a private placement on November 24, 2016 and December 20, 2016 (the "Private Placement") consisting of an aggregate of 6,250,000 units (the "Units") at a price of $0.20 per Unit for gross proceeds of $1,250,000. Each Unit consisted of one common share in the capital of the Company (a "Share") and one common share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to purchase one additional Share at an exercise price of $0.30 for a period of 12 months from the issuance date. In connection with the Private Placement, Lexington paid aggregate finder's fees of $80,400 and issued 502,500 common share purchase warrants (the "Finder Warrants"). Each Finder Warrant is exercisable for one Share at an exercise price of $0.30 per Share. 101,000 Finder Warrants are exercisable until November 24, 2017 and 401,500 Finder Warrants are exercisable until December 20, 2017. Pursuant to applicable securities laws, all securities issued in connection with the Private Placement were subject to a hold period of four months and one day from the date of issuance. The hold period on 1,260,000 Shares expired on March 25, 2017 and the hold period on 4,990,000 Shares expired on April 21, 2017. For further details on the acquisition and the Private Placement see the Company's final prospectus dated March 31, 2017 (a copy of which is available under the Company's SEDAR profile at www.sedar.com). The securities issued pursuant to the Transaction and the Private Placement have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities issued by the Company pursuant to the Transaction and the Private Placement are "restricted securities" as defined under Rule 144(a)(3) of the U.S. Securities Act and contain the appropriate restrictive legends as required under the U.S. Securities Act and Canadian Securities Administrators National Instrument 45-102. Stock Option Incentive Plan and Option Grant In connection with the Company's Exchange listing, the Company issued an aggregate 1,800,000 incentive stock options (the "Options") in accordance with the Company's stock option plan (the "Option Plan") to certain directors, officers and consultants of the Company. The Options entitle the respective optionee to purchase one Share at an exercise price of $0.20 per Share. All Options may be exercised until May 9, 2022 unless terminated pursuant to the terms of the Option Plan. The Options and any Shares issued upon exercise will be subject to a four-month resale restriction from the date of grant. The Option Plan adopted by the board of directors (the "Board") concurrent with the closing of the Transaction is a "rolling" stock option plan, pursuant to which the Board may from time to time, in its discretion, and in accordance with Exchange and regulatory requirements, grant to directors, officers, employees and consultants, non-assignable and non-transferable options to purchase shares of common, provided that the number of Shares reserved for issuance will not exceed 10% of the then issued and outstanding common shares of the Company. About Lexington Biosciences, Inc. ( : LNB) Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium -- the vital innermost lining of a person's cardiovascular system. Currently, this is measured by using ultrasound. The HeartSentry core technology was created at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. The company is in the final stages of releasing the developed product for clinical studies. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/. CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to the completion of the listing of the Company's shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


"Although prognostic signatures have become widely established in prostate cancer research, the development of signatures that can predict response to individual therapies has been a difficult proposition," said Felix Feng, M.D., Associate Professor of Radiation Oncology and Urology at the University of California, San Francisco. "The clinical validation of the established breast cancer PAM50 signature for men with prostate cancer will help physicians to predict which patients are most likely to benefit from postoperative hormone therapy, allowing for personalized patient selection, potentially improving treatment outcomes and sparing many patients from unnecessary toxicity." The study included clinical and genomic data from 3,782 retrospectively and prospectively collected radical prostatectomy samples in the Decipher GRID, and found that the PAM50 signature had the ability to consistently classify prostate cancer into luminal A, luminal B, and basal-like subtypes. The study determined that luminal B prostate cancers are the most aggressive, with nearly half the patients experiencing metastasis at 10 years. Further, luminal B patients were found to respond better to post-operative ADT, suggesting that these patients should be prioritized for early initiation of hormone therapy. "Ultimately we envision the field moving towards a biomarker driven approach, whereby prognostic signatures are used to select patients with aggressive disease and predictive signatures are used to select specific therapies," said Doug Dolginow, M.D., chief executive officer of GenomeDx. "The combination of a genomic test such as Decipher and basal-luminal subtypes could allow for selection of patients who need postoperative ADT, improving the personalization of therapy for patients with prostate cancer." GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment. Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment. More information is available at www.deciphertest.com and www.deciphergrid.com GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California. UC Disclaimer  The information stated above was prepared by GenomeDX Biosciences and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of GenomeDX, or any of its products, by The Regents of the University of California, its officers, agents and employees. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedxs-decipher-grid-aids-in-development-and-validation-of-molecular-subtypes-in-prostate-cancer-that-predict-response-to-hormone-therapy-300455996.html

Loading Biosciences collaborators
Loading Biosciences collaborators